Is Amgen (AMGN) Reasonable Or Rich As Cash Flow Improves?
Amgen stock has logged a strong 5 year run, yet current valuation checks send mixed signals as the intrinsic value estimate suggests a discount while market based multiples look closer to fair. Over 5 years, Amgen has returned 134.2%, which means anyone looking at the stock today is weighing fresh gains against the chance that the easy part of the move is already behind it. New clinical data around Repatha and Tezspire can support expectations for future cash flows, while ongoing trial and...
YahooyesterdayAMGN
TEZSPIRE’s Positive EoE Phase 3 Results Could Be A Game Changer For Amgen (AMGN)
Amgen and AstraZeneca recently reported positive Phase 3 CROSSING results showing TEZSPIRE improved histologic remission and dysphagia symptoms in patients with eosinophilic esophagitis, with effects sustained through week 52 and a safety profile broadly consistent with prior use. Because EoE remains poorly controlled for nearly half of patients on existing therapies, TEZSPIRE’s epithelial-targeting mechanism could meaningfully expand its role beyond severe asthma and nasal polyps if...
YahooyesterdayAMGN
AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE
Amgen (NASDAQ: AMGN) will present at the 2026 Wells Fargo Healthcare Conference at 11:00 a.m. ET on Thursday, September 10, 2026. Thomas Dittrich, executive vice president and chief financial officer at Amgen, Paul Burton, M.D., Ph.D, senior vice president and chief medical officer at Amgen, and Kave Niksefat, senior vice president of Global Marketing and Access at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to membe
YahooyesterdayAMGN
Rare-Disease Drug Tavneos Faces UK Withdrawal
CSL Vifor holds the U.K. authorization and is leading regulator talks
Yahoo2 days agoAMGN
J&J Faces Multiple Headwinds: Can the Healthcare Giant Sustain Growth?
JNJ faces Stelara and upcoming drug LOEs, MedTech weakness and talc litigation, but targets accelerated growth in 2026 and beyond.
Yahoo2 days agoAMGN
2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB
Complement Inhibitors Market Complement Inhibitors Market Dublin, Sept. 02, 2026 (GLOBE NEWSWIRE) -- The "Complement Inhibitors Market (2nd Edition): Distribution by Target Disease Indication, Therapeutic Area, Type of Molecule, Target Pathway, Type of Therapy, Route of Administration, Leading Drugs, Key Geographical Regions and Leading Players - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global complement inhibitors market is projected to increase fr
Yahoo2 days agoAMGN
Heart-Drug Breakthroughs Can’t Stop Biotech Stocks From Sliding
Impressive results came out on drugs from Amgen, Arrowhead Pharmaceuticals, and Crispr Therapeutics. Their shares are all lower this week.
Yahoo2 days agoAMGN
Stocks rise for first time in four sessions as Treasury yields take breather: Live updates
Stocks rose on Wednesday as U.S. Treasury yields took a breather from the recent run-up that sent them to multiyear highs.
CNBC2 days agoAMGN
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Eric Foster as chief commercial officer. Mr. Foster will lead Beam’s commercial organization and strategy as the company advances multiple product candidates across its hematology and genetic disease franchises toward potential launches. “Eric is an exceptional biopharmaceutical leader w
Yahoo3 days agoAMGN
One Of Amgen's Biggest Moneymakers Cuts The Risk Of Dying By 20%
Amgen said Monday its cholesterol buster, Repatha, reduced the risk of death by 20% in a study of more than 12,000 high-risk patients.
Yahoo3 days agoAMGN
How Is Amgen’s Stock Performance Compared to Other General Drug Manufacturers
AMGN has outperformed the broader market over the past year, while analysts remain moderately bullish on its future prospects.
Yahoo4 days agoAMGN
AstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Disease
AstraZeneca & Amgen’s Tezspire achieves significant Phase 3 CROSSING trial results in eosinophilic esophagitis (EoE) treatment.
Benzinga8 days agoAMGN
AstraZeneca, Amgen Report Phase III Results For TEZSPIRE In Eosinophilic Esophagitis; TEZSPIRE Meets Key Endpoints In Phase III CROSSING Trial
Statistically significant and clinically meaningful disease and symptom improvements compared to placebo maintained through week 52Efficacy in a third epithelial-driven inflammatory disease supports broad potential of
Benzinga8 days agoAMGN
Amgen And AstraZeneca's TEZSPIRE Meets Both Co-Primary And All Key Secondary Endpoints In Phase 3 CROSSING Trial For Eosinophilic Esophagitis
Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports Broad Potential of
Benzinga8 days agoAMGN
Here’s How Much You Would Have Made Owning Amgen Stock In The Last 15 Years
Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.91% on an annualized basis producing an average annual return of 14.92%. Currently, Amgen has a market capitalization of $241.16 billion.
Benzinga10 days agoAMGN
Regeneron: Why I Still See Upside After The Rally
Regeneron Pharmaceuticals, Inc. stock outlook: Eylea pressure eases as Dupixent jumps; FDA OKs Pasatru. Read why REGN stock is a buy.
SeekingAlpha10 days agoAMGN
Lilly's Multiple Assumes Less Growth Than You Think
Consensus asks Eli Lilly for far less growth than it is delivering, and for margins to keep climbing from a level it only just reached.
Yahoo13 days agoAMGN
Why the Dow Is Beating the Nasdaq Again
Suddenly the Nasdaq couldn’t hold onto early gains, and you can probably guess which stocks are to blame. The Nasdaq Composite was hovering around breakeven after a wave of selling hit chips and AI infrastructure stocks. The S&P 500 was still up 0.3%.
Yahoo14 days agoAMGN
Amgen (AMGN) Gets A Fresh Target, Is It Fully Priced?
Analyst reaction to Amgen’s latest quarter Amgen (AMGN) is back in focus after Argus raised its price target to $460 from $375 while maintaining a Buy rating, following second quarter results and reported progress across the company’s drug portfolio. See our latest analysis for Amgen. Beyond the latest quarter, Amgen’s recent news sits against strong momentum in the stock, with a 30 day share price return of 18.49% and a 1 year total shareholder return of 51.76%. This points to building...
Yahoo14 days agoAMGN
SCHD: We Were Horribly Wrong
SCHD beat bearish macro trends as ABT, MRK & AMGN surged. Learn why dividend growth makes waiting costlyâand what to do now.
SeekingAlpha14 days agoAMGN
Global DLL3 Targeted Therapies Market 2026-2030: Profiles Amgen, Zai Lab, Boehringer Ingelheim and Phanes Therapeutics
Dublin, Aug. 20, 2026 (GLOBE NEWSWIRE) -- The "Global DLL3 Targeted Therapies Market Opportunity, Approved Therapy Sales, Pricing, Proprietary Development Platforms & Clinical Trials Insight 2030" has been added to ResearchAndMarkets.com's offering. Key Report Highlights: Global DLL3 targeted therapies market opportunity projected to exceed USD 2 billion by 2030Analysis of current market trends, growth drivers and future commercial opportunitiesUnited States expected to dominate market sales, wh
Yahoo15 days agoAMGN
Piper Sandler Maintains Overweight on Amgen, Raises Price Target to $457
Piper Sandler analyst David Amsellem maintains Amgen (NASDAQ:AMGN) with a Overweight and raises the price target from $427 to $457.
Benzinga15 days agoAMGN
Argus Research Maintains Buy on Amgen, Raises Price Target to $460
Argus Research analyst Jasper Hellweg maintains Amgen (NASDAQ:AMGN) with a Buy and raises the price target from $375 to $460.
Benzinga16 days agoAMGN
How to Build $7,200 a Month in Dividend Income Without Selling a Single Share
Generating $86,400 a year in dividends sounds like a number reserved for the ultra-wealthy, but the capital required swings dramatically depending on one variable most investors overlook before they build a single position.
Yahoo21 days agoAMGN
Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover
Wave Life Sciences has lost nearly 70% of its value this year, yet its RNA platform spans obesity, rare liver disease, and genetic disorders in ways that could make it irresistible to the right buyer. The question is which pharma giant moves first.
Yahoo22 days agoAMGN
Amgen’s Q2 Earnings Call: Our Top 5 Analyst Questions
Amgen’s second quarter results reflected broad-based portfolio momentum, with management crediting double-digit growth in key products like Repatha, EVENITY, and TEZSPIRE for the company’s outperformance versus Wall Street estimates. CEO Robert Bradway highlighted that 22 products achieved double-digit sales growth, and 17 products annualized over $1 billion in sales, noting, “Our strong results were driven by the breadth and depth of our portfolio and once again demonstrate our ability to grow
Yahoo22 days agoAMGN
BeOne Medicines Ltd (ONC) (Q2 2026) Earnings Call Highlights: Revenue Surges 30% to $1. ...
BeOne Medicines Ltd (ONC) delivers robust Q2 2026 results with record BRUKINSA sales, raises full-year guidance, and advances a promising oncology pipeline.
Yahoo22 days agoAMGN
Big Pharma's Future Growth Rests on Chinese Science? Expert Says: 'We Can't Ban Our Way Out of This'
China’s science surge is reshaping global drug development as Washington moves to counter Beijing’s growing influence in medicine.
Benzinga22 days agoAMGN
These dow jones stocks are moving in today's session
Stay informed about the performance of the dow jones index one hour before the close of the markets on Friday. Uncover the top gainers and losers in today's session for valuable insights.
ChartMilllast monthAMGN
Amgen Q2 Earnings Preview: Will the Beat Streak Continue?
Amgen heads into Q2 earnings with a history of beats as investors watch key drug sales trends and seek updates on its MariTide obesity candidate.
Yahoolast monthAMGN
The Signs Before Eli Lilly Stock Surged Were All On The Record
Eli Lilly stock ran on a story that was public and dated long before the price moved, and reading it right still would not have put you ahead of every peer.
Yahoolast monthAMGN
LLY Stock: Collect 12% Now, In Exchange For Capping Upside At 15%
Here is a way to get paid a meaningful income now on your Eli Lilly shares, income you keep no matter what the stock does, in exchange for agreeing to sell at a price above today's if it climbs there.
Yahoolast monthAMGN
FIRST AMGEN SCHOLARS PROGRAM IN INDIA LAUNCHES AT IIIT HYDERABAD
Amgen (NASDAQ: AMGN) today announced the launch of the first Amgen Scholars Program in India at the International Institute of Information Technology Hyderabad (IIIT Hyderabad), bringing the globally respected undergraduate summer research program to India for the first time.
Yahoolast monthAMGN
AMGEN ANNOUNCES 2026 THIRD QUARTER DIVIDEND
Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the third quarter of 2026. The dividend will be paid on September 11, 2026, to all stockholders of record as of the close of business on August 21, 2026.
Yahoolast monthAMGN
What Analyst Projections for Key Metrics Reveal About Amgen (AMGN) Q2 Earnings
Besides Wall Street's top-and-bottom-line estimates for Amgen (AMGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
Yahoolast monthAMGN